Abstract AB0669 – Table 1

	Optimized Group N=23	Non-Optimized Group N=42	P
Demographic features			
Age (years) (mean±S.D.)	37.2±13.4	39.1±9.3	0.5
Sex (n, %)	15/8	19/23	0.13
Positive HLA-B51 (%)	61	74	0.26
Duration of uveitis (months) prior to ADA (median [IQR])	43 [23-74.5]	24 [6-36]	0.1
Previous immunosuppressants (n) (mean±S.D.)	2±1.1	1.7±1.1	0.3
Ocular pattern at ADA onset			
BCVA (mean±S.D.)	0.81±0.36	0.55±0.33	0.46
AC cells (median [IQR])	0 [0-2]	1 [0-2]	0.85
Vitritis (median [IQR])	1 [0-2]	1 [0-2]	0.66
OCT (mean±S.D.)	306.7±122.9	332.8±129.1	0.51
Ocular pattern at last visit			
BCVA (mean±S.D.)	0.89±0.19	0.77±0.25	<0.01
AC cells (median [IQR])	0 [0-0]	0 [0-0]	0.7
Vitritis (median [IQR])	0 [0-0]	0 [0-0]	0.3
OCT (mean±S.D.)	250.5±17.9	249±26.1	0.87
Follow-up on ADA therapy, months, (mean±S.D.)			
Relapses, n (per 100 patients/year)	2 (3.0)	4 (4.4)	0.66
Severe side-effects, n (per 100 patients/year)	0 (0)	4 (4.4)	0.19
Cost mean, euros per year	6101.25	12339.48	<0.01

Conclusions: ADA optimisation in BD uveitis refractory to conventional therapy is effective, safe and cost-effective.

REFERENCES:

- Calvo-Río V, Blanco R, Beltrán E, et al. Anti-TNF-alfa therapy in patients with refractory uveitis due to Behçet's disease: a 1-year- follow-up study of 124 patients. *Rheumatol*. 2014; 53(12):2223–31
- Santos-Gómez M, Calvo-Río V, Blanco R, et al. The effect of biologic therapy different from infliximab or adalimumab in patients with refractory uveitis due to Behçet's disease: results of a multicentre open-label study. *Clin Exp Rheumatol*. 2016; 34 (6 Suppl 102):S34-S40

Disclosure of Interest: None declared

DOI: 10.1136/annrheumdis-2018-eular.3963

AB0670

SHORT AND LONG-TERM TREATMENT WITH INFLIXIMAB IN RETINAL VASCULITIS OF BEHÇET'S DISEASE. MULTICENTER STUDY OF 72 PATIENTS

J.L. Martín-Varillas¹, V. Calvo-Río¹, R. Demetrio-Pablo¹, B. Atienza-Mateo¹, J. Loricera¹, M.V. Hernández², A. Adán², M. Mesquida², D. Peiteado³, E. Pato⁴, D. Díaz⁴, L. Martínez⁵, E. Valls⁵, M.A. Caracul⁶, A.M. García⁷, J.M. Herrera⁸, M. Cordero⁹, C. Montilla¹⁰, A. Fonollosa¹¹, A. Atanes¹², F.F. Hernández¹³, I. Torre¹⁴, O. Maiz¹⁵, A. Blanco¹⁵, C. Espartero¹⁶, N. Ortego¹⁷, E. Raya¹⁷, M. Gandía¹⁸, F.J. López¹⁹, M. Alcalde²⁰, C. Fernández²¹, Ó. Ruiz²², F. Jiménez²², R. Almodovar²³, C. Carrasco²⁴, L. Linares²⁵, F. Romero²⁶, S. Insua²⁷, S. González²⁸, M. Hernández²⁹, E. Beltrán³⁰, J. Cruz³¹, C. Fernández³¹, E. Aurecochea³², M.A. González-Gay¹, R. Blanco¹. ¹Rheumatology and Ophthalmology, HUMV, IDIVAL, Santander; ²Rheumatology and Ophthalmology, H Clinic, Barcelona; ³Rheumatology, H La Paz; ⁴Rheumatology and Ophthalmology, H San Carlos, Madrid; ⁵Rheumatology and Ophthalmology, H Peset, Valencia; ⁶Rheumatology, H Córdoba, Córdoba; ⁷Rheumatology, H Toledo, Toledo; ⁸Ophthalmology, H Valladolid, Valladolid; ⁹Ophthalmology, H León, León; ¹⁰Rheumatology, H Salamanca, Salamanca; ¹¹Ophthalmology, H Cruces, Bilbao; ¹²Rheumatology, H Coruña, Coruña; ¹³Rheumatology, H Doctor Negrín, Las Palmas; ¹⁴Rheumatology, H Basurto, Bilbao; ¹⁵Rheumatology and Ophthalmology, H Donosti, San Sebastián; ¹⁶Rheumatology, H Móstoles, Madrid; ¹⁷Autoimmune Diseases, H San Cecilio, Granada; ¹⁸Rheumatology, H Puerta del Mar, Cádiz; ¹⁹Rheumatology, H Gregorio Marañón; ²⁰Rheumatology, H Severo Ochoa, Madrid; ²¹Rheumatology, H Elda, Alicante; ²²Rheumatology and Ophthalmology, H Miguel Servet, Zaragoza; ²³Rheumatology, H Alcorcón, Madrid; ²⁴Rheumatology, H Mérida, Mérida; ²⁵Rheumatology, H Arritxaca, Murcia; ²⁶Rheumatology, Jiménez Díaz, Madrid; ²⁷Rheumatology, H Santiago Compostela, Santiago Compostela; ²⁸Rheumatology, H Cabueñes, Gijón; ²⁹Ophthalmology, H Valencia, Valencia; ³⁰Rheumatology, H del Mar, Barcelona; ³¹Rheumatology and Ophthalmology, H Pontevedra, Pontevedra; ³²Rheumatology, H Sierrallana, Torrelavega, Spain

Background: Retinal vasculitis (RV) is a serious complication of uveitis due to Behçet's disease (BD).¹⁻²

Objectives: We assess the short/long-term efficacy of Infliximab (IFX) in refractory RV of BD.

Methods: Multicenter study of patients with RV of BD refractory to corticosteroids and at least 1 conventional immunosuppressant (IS). We compared efficacy of IFX between baseline, 1st week, 1–6 months and 1–6 years.

Results: 72 patients/129 affected eyes (40♂/32♀) with mean age of 39.6±9.7 years. HLA-B51 was (+) in 63%. Before IFX onset, patients had received: oral/e.v. glucocorticoids (n=98), CyA (n=56), AZA (n=43), MTX (n=34) and other IS (n=22). IFX was used as monotherapy in 17 patients and combined with conventional IS in the remaining 55.

IFX dose was as follows: 3 mg/kg/4–8 w (n=5), 4 mg/kg/4 w (n=1), 5–5.5 mg/kg/4–8 w (n=66).

Following IFX onset, an improvement in RV was seen, as well as in the other ocular outcomes. This enhancement was maintained (table 1).

After a mean follow-up of 26.5±22.1 months, IFX was discontinued in 44: remission (n=15), primary failure (n=16), preference of another route of administration (n=8), pregnancy (n=1) and adverse effects (n=4).

Abstract AB0670 – Table 1

	Baseline	1 st week	1 st month	3 rd month	6 th month	1 st year	2 nd year	3 rd year	4 th year	5 th year	6 th year
Retinal Vasculitis (n, affected eyes, %)	117 (100%)	93 (79.5%)	45 (38.5%)	21 (17.9%)	13 (11.1%)	4 (3.4%)	4 (3.4%)	3 (2.6%)	1 (0.9%)	0 (0%)	0 (0%)
BCVA (mean±SD)	0.41±0.31	0.45±0.32	0.57±0.33	0.63±0.34	0.63±0.34	0.63±0.35	0.63±0.35	0.61±0.33	0.63±0.32	0.66±0.37	0.66±0.37
Tyndall (median [IQR])	1 [0-2]	0 [0-2]	0 [0-0]	0 [0-0]	0 [0-0]	0 [0-0]	0 [0-0]	0 [0-0]	0 [0-0]	0 [0-0]	0 [0-0]
Vitritis (median [IQR])	1 [0-2]	1 [0-2]	0 [0-0]	0 [0-0]	0 [0-0]	0 [0-0]	0 [0-0]	0 [0-0]	0 [0-0]	0 [0-0]	0 [0-0]
OCT (mean±SD)	346.9±140.7	339.6±125.6	310.6±111.4	285.4±74.5	264.7±57.1	268.6±52.7	265.2±43.7	253.8±31.0	239.8±33.8	208.6±26.0	194.7±4.1

*p<0.05

Conclusions: IFX seems an effective short/long-term treatment in RV of BD.

REFERENCES:

- Calvo-Río V, Blanco R, Beltrán E, et al. Anti-TNF-alfa therapy in patients with refractory uveitis due to Behçet's disease: a 1-year-follow-up study of 124 patients. *Rheumatol*. 2014; 53(12):2223–31
- Santos-Gómez M, Calvo-Río V, Blanco R, et al. The effect of biologic therapy different from infliximab or adalimumab in patients with refractory uveitis due to Behçet's disease: results of a multicentre open-label study. *Clin Exp Rheumatol*. 2016; 34 (6 Suppl 102):S34-S40

Disclosure of Interest: None declared

DOI: 10.1136/annrheumdis-2018-eular.4015

AB0671

FIRST DOCUMENTATION OF RS3PE AFFECTING THE HANDS ON 18F-FDG WHOLE BODY PET/CT IN POLYMYALGIA RHEUMATICA

C.E. Owen^{1,2}, A.M. Poon^{2,3}, L.P. Yap⁴, J.L. Leung^{1,2}, D.F. Liew^{1,2}, S.T. Lee^{2,3,5}, A. M. Scott^{2,3,5}, R.R. Buchanan^{1,2}. ¹Rheumatology, Austin Health, Heidelberg VIC; ²Medicine, University of Melbourne, Parkville VIC; ³Molecular Imaging and Therapy; ⁴Radiology, Austin Health; ⁵Olivia Newton-John Cancer Research Institute, Heidelberg VIC, Australia

Background: Remitting seronegative symmetrical synovitis with pitting oedema (RS3PE) syndrome describes a clinical entity characterised by distal synovitis with pitting oedema, the absence of rheumatoid factor (Rf) and an excellent response to glucocorticoid therapy.^[1] Most frequently associated with polymyalgia rheumatica (PMR), tenosynovial sheath inflammation represents the magnetic resonance imaging (MRI) hallmark of this condition, with concomitant joint synovitis also present in some cases.^[1] More recently, diffusely increased ¹⁸F-fluorodeoxyglucose (¹⁸F-FDG) uptake in the soft tissues around the ankles and feet has been described as the correlate of RS3PE on whole body positron emission tomography/computed tomography (PET/CT).^[2]

Objectives: To document the clinical and radiologic appearance of RS3PE syndrome affecting the hands on MRI and whole body PET/CT in PMR patients.

Methods: Patients with newly diagnosed PMR were prospectively recruited as part of the Melbourne Predictors of Relapse in PMR (MPR-PMR) study. A standard physical examination was carried out with specific focus upon the presence of peripheral synovitis and pitting oedema. In patients with findings suggestive of RS3PE, clinical photography was undertaken. All study participants underwent a whole body PET/CT scan including dedicated views of the hands using the Philips T/F machine prior to prednisolone commencement. To precisely identify anatomic correlates of abnormal ¹⁸F-FDG uptake in patients with RS3PE, MRI of the wrist and hand was performed using a 1.5 Tesla magnet.

Results: 3/35 patients (0.86%) were noted to have distal synovitis and pitting oedema of the hands at enrolment. Mean age was 70.9±10.1 years, two patients were male, and all were Caucasian. Rf and anti-citrullinated peptide autoantibodies were negative in all cases. On whole body PET/CT, intense ¹⁸F-FDG uptake was visualised at the wrist joint and hand in a distinctive volar distribution. MRI of the wrist and hand in two participants (contraindicated in the third)

confirmed flexor tenosynovitis (white arrows) and intercarpal synovitis (yellow arrow) in keeping with RS3PE syndrome.

Abstract AB0671 – Figure 1

Conclusions: On whole body PET/CT, RS3PE syndrome is associated with a distinctive volar pattern of abnormal ^{18}F -FDG uptake at the wrist and hand, which correlates with flexor tenosynovitis and intercarpal synovitis as previously described on MRI.

REFERENCES:

- [1] Cantini F, Salvarani C, Olivieri I, et al. Remitting seronegative symmetrical synovitis with pitting oedema (RS3PE) syndrome: a prospective follow up and magnetic resonance imaging study. *Annals of the Rheumatic Diseases*. 1999;58(4):230–6.
- [2] Wang J, Pu C, Wang Z, Yang J. Remitting Seronegative Symmetrical Synovitis With Pitting Edema: Appearance on FDG PET/CT. *Clin Nucl Med*. 2017;42(6):492–5.

Disclosure of Interest: None declared

DOI: 10.1136/annrheumdis-2018-eular.6132

AB0672 18F-FDG WHOLE BODY PET/CT AS A DIAGNOSTIC TEST FOR POLYMYALGIA RHEUMATICA IN PATIENTS WITH NORMAL INFLAMMATORY MARKERS

C.E. Owen^{1,2}, E. Martin¹, A.M. Poon^{2,3}, J.L. Leung^{1,2}, D.F. Liew^{1,2}, S.T. Lee^{2,3,4}, A. M. Scott^{2,3,4}, R.R. Buchanan^{1,2}. ¹Rheumatology, Austin Health, Heidelberg VIC; ²Medicine, University of Melbourne, Parkville VIC; ³Molecular Imaging and Therapy, Austin Health; ⁴Olivia Newton-John Cancer Research Institute, Heidelberg VIC, Australia

Background: Despite abnormal C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR) being required in the 2012 EULAR/ACR classification criteria, 7%–20% of polymyalgia rheumatica (PMR) patients possess normal inflammatory markers at diagnosis.¹ A characteristic pattern of ^{18}F -fluorodeoxyglucose (^{18}F -FDG) uptake is seen on whole body positron emission tomography/computed tomography (PET/CT) in PMR, hence this imaging modality may be a useful diagnostic test in this clinical scenario.

Objectives: To report the utility of whole body PET/CT for diagnosing PMR in patients with normal inflammatory markers and compare the clinical and radiologic characteristics of this subgroup with patients from the Melbourne Predictors of Relapse in PMR (MPR-PMR) study.

Methods: Patients presenting with clinical features of PMR according to the 2012 EULAR/ACR classification criteria but normal CRP and ESR underwent ^{18}F -FDG PET/CT as part of their diagnostic work-up. A whole body scan from skull vertex to feet (including dedicated hand views) was performed using the Phillips T/F machine prior to prednisolone commencement. Qualitative and semi-quantitative (standardised uptake value maximum [SUV_{max}]) scoring of abnormal ^{18}F -FDG uptake was undertaken. Newly diagnosed and untreated PMR patients who underwent the same ^{18}F -FDG PET/CT protocol as part of the MPR-PMR study were used as the comparator group. Statistical analysis was conducted using Stata 13.1 (StataCorp, College Station, TX, USA).

Results: Three patients with normal inflammatory markers (Median CRP 1 [0.9–2], median ESR 6^{1–7}) underwent ^{18}F -FDG PET/CT. Mean age was 60.15±7.55

years, two patients (66.67%) were male and all were Caucasian. Shoulder and hip pain was present in all cases, but only one patient reported peripheral joint involvement. Median early morning stiffness (EMS) was 30 min.^{15–60} On whole body PET/CT, characteristic ^{18}F -FDG uptake was visualised in each patient at the shoulder capsule, trochanteric bursae and adjacent to the ischial tuberosities, with hip capsule involvement similarly present in 2/3. When compared with 35 patients from the MPR-PMR study, there were no statistically significant differences in the clinical characteristics nor the distribution or intensity of abnormal ^{18}F -FDG uptake between the two populations.

Conclusions: In patients with suggestive clinical features but normal inflammatory markers, whole body PET/CT may be utilised to confirm a diagnosis of PMR.

REFERENCE:

- [1] Cantini F, Salvarani C, Olivieri I, et al. Erythrocyte sedimentation rate and C-reactive protein in the evaluation of disease activity and severity in polymyalgia rheumatica: a prospective follow-up study. *Seminars in Arthritis & Rheumatism*. 2000;30(1):17–24.

Disclosure of Interest: None declared

DOI: 10.1136/annrheumdis-2018-eular.5280

AB0673 ANCA-ASSOCIATED VASCULITIS AND INFECTIONS: RETROSPECTIVE ANALYSIS IN A REFERRAL CENTRE

J. Álvarez Troncoso, Z. Iannaccone, E. Álvaro Valiente, C. Busca Arenzana, L. Ramos Ruperto, G. Daroca Bengoa, J. Vasquez Manau, F. Arnalich Fernández, J.J. Ríos Blanco. *Internal Medicine, Hospital Universitario La Paz, Madrid, Spain*

Background: The antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) are rare multisystem autoimmune diseases of unknown cause, characterised by inflammatory cell infiltration causing necrosis of blood vessels. The AAV comprise granulomatosis with polyangiitis (GPA), microscopic polyangiitis (MPA) and eosinophilic granulomatosis with polyangiitis (EGPA). The AAV are autoimmune diseases with potentially severe systemic involvement that require prolonged immunosuppressive therapy. Infection is a frequent complication in AAV and is associated with increased morbidity and mortality.

Objectives: The aim of this study was to define epidemiology, ANCA patterns, treatments, infections and outcomes of a series of 39 patients with AAV.

Methods: We retrospectively analysed 39 patients diagnosed with AAV between 1995 and 2017 from the Internal Medicine Department of a Spanish referral centre.

Results: A total of 39 patients were reviewed. 23 female (58.9%). Mean age at diagnosis was 55.6 years. Median time delay to diagnosis was 7.6 weeks. Median follow-up was 91.3 months. Most frequent AAV was MPA with 18 patients (46.2%), followed by GPA with 11 (28.2%) and EGPA with 10 (25.6%). 6 patients (15.4%) had a concomitant autoimmune disease: Systemic sclerosis,² Antiphospholipid syndrome,² Lupus¹ and Sjögren.¹ Only 2 patients (5.1%) had previous infection with hepatitis C virus. Regarding the treatments, all patients received corticoids (bolus 24 patients, 61.5%), 29 (74.4%) cyclophosphamide, 10 (25.6%) rituximab, 19 (48.7%) azathioprine, 4 (10.3%) mycophenolate and 1 (2.6%) methotrexate. 16 patients presented post-treatment lymphopenia, 5 pancytopenia, and 15 hypogammaglobulinemia. 21 patients (53.8%) presented any infection after the diagnosis. The most frequent were bacterial infections (15 patients), presenting 9 patients with sepsis criteria (7 due to gram-negative organisms). 9 opportunistic infections were described: 3 infections by cytomegalovirus, 5 by tuberculosis and 1 by *Mycobacterium avium*. There were no cases of *Pneumocystis jirovecii* despite the fact that only 16 patients (41%) performed primary prophylaxis. The factors associated with increased risk of infections were: lymphopenia, pancytopenia and increased BVAS ($p<0.05$). 6 patients had died at the time of the study (3 associated with infections, 2 with neoplasms and 1 directly with AAV). The Charlson index performed at the time of the study was the best predictor of mortality ($p<0.01$).

Conclusions: Infections were a frequent complication in patients with AAV and one of the main causes of mortality. Risk factors were lymphopenia, pancytopenia and increased BVAS. Bacterial infections were the most frequent but opportunistic infections must be taken into account.

REFERENCE:

- [1] Kronbichler A, Jayne DR, Mayer G. Frequency, risk factors and prophylaxis of infection in ANCA-associated vasculitis. *Eur J Clin Invest*. 2015 Mar;45(3):346–68.

Disclosure of Interest: None declared

DOI: 10.1136/annrheumdis-2018-eular.4286